HHQ16

Cat. No.:	HY-160706
CAS No.:	2620471-66-9
Molecular Formula:	$C_{30}H_{48}F_2O_4$
Molecular Weight:	510.7
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling[1].
In Vitro	HHQ16 (100 nM, 6 h) binds to lnc9456 with high-affinity and induces its degradation in HL-1 mouse cardiomyocytes[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HHQ16 (1- 100 mg/kg, oral gavage, daily for 4 weeks) effectively reverses the left anterior descending coronary artery ligation (LADL)-induced deterioration of cardiac function and structural remodeling in mice[1]. HHQ16 (10 mg/kg, p.o., 2 weeks) decreases the high level of lnc9456 in the heart and regress the remodeling associated changes in AAV-lnc9456 mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	left anterior descending coronary artery ligation (LADL)-induced heart failure mice[1]
Dosage:	1- 100 mg/kg
Administration:	oral gavage, daily for 4 weeks
Result:	Increased theeft ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) of the mice. Reduced the enlarged heart size and the heart weight to body surface area ratio (HW/BSA). Reversed LADL-induced hypertrophy by decreasing the cell volume (size) and slippage (disorderly aligned myocytes). Reversed LADL-induced increase in ANP, BNP, β-MHC, and hypertrophic expression of ANP and BNP.

REFERENCES

[1]. Wan J, et al. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456. Signal Transduct Target Ther. 2023 Oct 19;8(1):414.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA